Published in ILAR J on January 01, 2014
BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses. Neurobiol Dis (2014) 0.90
Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocin-induced diabetic C57Bl/6J mice. J Peripher Nerv Syst (2014) 0.89
The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes. Diabetes (2015) 0.79
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron (2017) 0.77
Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice. J Diabetes Complications (2015) 0.76
Arterial Calcification in Diabetes Mellitus: Preclinical Models and Translational Implications. Arterioscler Thromb Vasc Biol (2016) 0.75
Sensory and autonomic function and structure in footpads of a diabetic mouse model. Sci Rep (2017) 0.75
Differential impact of type-1 and type-2 diabetes on control of heart rate in mice. Auton Neurosci (2015) 0.75
Leptin Status Alters Buprenorphine-Induced Antinociception in Obese Mice with Dysfunctional Leptin Receptors. Neurosci Lett (2017) 0.75
Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods (1994) 23.05
Prevalence of diabetes among men and women in China. N Engl J Med (2010) 19.98
Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care (2010) 6.64
A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes (1997) 3.83
The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity (1997) 3.44
Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes (2007) 2.95
Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res (2010) 2.87
Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol (2006) 2.81
Maternal environment and genotype interact to establish diabesity in mice. Genome Res (2000) 2.00
Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes (2009) 1.99
Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol (2012) 1.99
High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes (2007) 1.85
Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol (2011) 1.85
Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve (2001) 1.85
The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes (2006) 1.84
Mouse models of diabetic neuropathy. Neurobiol Dis (2007) 1.76
Vascular factors in diabetic neuropathy. Diabetologia (1994) 1.74
Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest (2001) 1.73
Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes (2009) 1.64
Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J (2004) 1.64
Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care (2004) 1.58
Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism (1998) 1.54
Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol (2002) 1.53
Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst (2009) 1.52
Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proc Natl Acad Sci U S A (1982) 1.51
Genotoxicity of streptozotocin. Mutat Res (2002) 1.51
Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Proc Natl Acad Sci U S A (1998) 1.49
Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Physiol Endocrinol Metab (2002) 1.47
Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. Am J Ther (2005) 1.45
Retracted Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes (2007) 1.44
High-fat diet-induced hyperglycemia and obesity in mice: differential effects of dietary oils. Metabolism (1996) 1.43
The genetics of diabetes susceptibility in mice. FASEB J (1989) 1.40
Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil (2005) 1.38
SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp Neurol (2007) 1.38
GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes (1998) 1.36
The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Protoc Immunol (2001) 1.31
Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett (2008) 1.31
Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation (2005) 1.28
Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A (2010) 1.26
Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? Diabetes (2005) 1.25
Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Exp Neurol (2007) 1.21
A phytoestrogen-rich diet increases energy expenditure and decreases adiposity in mice. Environ Health Perspect (2007) 1.19
Fat intake affects adiposity, comorbidity factors, and energy metabolism of sprague-dawley rats. Obes Res (2002) 1.19
Insulin resistance in the nervous system. Trends Endocrinol Metab (2012) 1.18
Streptozotocin interactions with pancreatic beta cells and the induction of insulin-dependent diabetes. Curr Top Microbiol Immunol (1990) 1.18
Comparisons of diets used in animal models of high-fat feeding. Cell Metab (2008) 1.17
Sonic hedgehog induces arteriogenesis in diabetic vasa nervorum and restores function in diabetic neuropathy. Arterioscler Thromb Vasc Biol (2004) 1.17
Peripheral neuropathy in mutant diabetic mouse [C57BL/Ks (db/db)]. Acta Neuropathol (1978) 1.16
Diabetic neuropathy: a clinical and histological study on the significance of vascular affections. Acta Med Scand Suppl (1959) 1.16
Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes (2008) 1.16
Early loss of peptidergic intraepidermal nerve fibers in an STZ-induced mouse model of insensate diabetic neuropathy. Pain (2008) 1.15
Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets (2008) 1.14
Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia (2012) 1.13
Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes. Diabetes (2011) 1.13
Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes (2007) 1.11
Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci (2001) 1.10
Neurogenic factor-induced Langerhans cell activation in diabetic mice with mechanical allodynia. J Neuroinflammation (2013) 1.10
Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes (2004) 1.09
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia (2004) 1.08
Longitudinal evaluation of memory performance and peripheral neuropathy in the Ins2C96Y Akita mice. Behav Brain Res (2005) 1.07
Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes (2005) 1.07
Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice. Diabetes (2008) 1.07
Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice. Endocrinology (2008) 1.06
Phenotypic changes in diabetic neuropathy induced by a high-fat diet in diabetic C57BL/6 mice. Exp Diabetes Res (2011) 1.06
Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. J Neuropathol Exp Neurol (2009) 1.06
Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest (1984) 1.05
Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology (1987) 1.05
Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology (2002) 1.03
Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience (2011) 1.03
Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes (2006) 1.03
A reassessment of vascular factors in relation to intravascular coagulation. Diabetologia (1976) 1.02
Gender differences in the onset of diabetic neuropathy. J Diabetes Complications (2008) 1.00
Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. J Neuropathol Exp Neurol (2012) 0.98
Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res (2012) 0.97
Selective changes in nocifensive behavior despite normal cutaneous axon innervation in leptin receptor-null mutant (db/db) mice. J Peripher Nerv Syst (2007) 0.96
Diabetic neuropathy: one disease or two? Curr Opin Neurol (2012) 0.95
Noninvasive monitoring of diabetes-induced cutaneous nerve fiber loss and hypoalgesia in thy1-YFP transgenic mice. Diabetes (2005) 0.95
Endoneurial capillary abnormalities in mild human diabetic neuropathy. J Neurol Neurosurg Psychiatry (1992) 0.94
Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. Free Radic Biol Med (2010) 0.93
Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress. Antioxid Redox Signal (2005) 0.92
High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy. Nutr Metab Cardiovasc Dis (2006) 0.92
Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy. Diabetes (2013) 0.91
A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes (2001) 0.91
Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice. Cold Spring Harb Perspect Med (2012) 0.91
Effect of varying dose and administration of streptozotocin on blood sugar in male CD1 mice. Proc West Pharmacol Soc (2011) 0.90
Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol (2011) 0.90
High-fat diet-induced neuropathy of prediabetes and obesity: effect of PMI-5011, an ethanolic extract of Artemisia dracunculus L. Mediators Inflamm (2010) 0.90
Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes (1990) 0.89
Bioenergetics in diabetic neuropathy: what we need to know. J Peripher Nerv Syst (2012) 0.88
INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice. FASEB J (2004) 0.87
Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology (2010) 0.87
Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice. Int J Mol Med (2011) 0.87
Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy. Exp Neurol (2012) 0.86
Neuron-astrocyte signaling network in spinal cord dorsal horn mediates painful neuropathy of type 2 diabetes. Glia (2012) 0.85
Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. Diabetes (1998) 0.85
Sciatic nerve morphology and morphometry in mature rats with streptozocin-induced diabetes. Acta Neuropathol (1994) 0.83
Endoplasmic reticulum stress contributes to prediabetic peripheral neuropathy. Exp Neurol (2012) 0.83
Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model. Proc Natl Acad Sci U S A (2012) 0.83
Comparative study of peripheral neuropathy and nerve regeneration in NOD and ICR diabetic mice. J Peripher Nerv Syst (2011) 0.83
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. J Pharm Pharmacol (2008) 0.81
Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 7.81
Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care (2006) 3.47
Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death". Acad Med (2012) 3.43
Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care (2010) 3.20
Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev (2004) 2.83
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Diabetic neuropathy: mechanisms to management. Pharmacol Ther (2008) 2.57
Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. Circ Res (2008) 2.48
Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet (2009) 2.23
High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J (2002) 2.18
Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes (2009) 1.99
Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol (2012) 1.99
Stem cell technology for neurodegenerative diseases. Ann Neurol (2011) 1.93
Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol (2014) 1.92
Microvascular complications of impaired glucose tolerance. Diabetes (2003) 1.88
Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells (2012) 1.87
Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol (2011) 1.85
Aligned electrospun nanofibers specify the direction of dorsal root ganglia neurite growth. J Biomed Mater Res A (2007) 1.83
Mouse models of diabetic neuropathy. Neurobiol Dis (2007) 1.76
Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J (2005) 1.75
Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes (2009) 1.64
Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev (2011) 1.62
How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol (2010) 1.60
Control of cell survival by IGF signaling pathways. Growth Horm IGF Res (2002) 1.56
Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst (2009) 1.52
Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev (2012) 1.51
SciMiner: web-based literature mining tool for target identification and functional enrichment analysis. Bioinformatics (2009) 1.45
SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. FASEB J (2009) 1.45
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol (2008) 1.44
Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology (2006) 1.44
Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord (2008) 1.40
Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology (2009) 1.39
IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis (2004) 1.39
SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp Neurol (2007) 1.38
The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst (2008) 1.36
The design of electrospun PLLA nanofiber scaffolds compatible with serum-free growth of primary motor and sensory neurons. Acta Biomater (2008) 1.36
Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J (2004) 1.33
Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. Neurobiol Dis (2006) 1.33
Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 1.32
Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery (2012) 1.27
Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst (2003) 1.26
Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A (2010) 1.26
Mitochondrial DNA (mtDNA) biogenesis: visualization and duel incorporation of BrdU and EdU into newly synthesized mtDNA in vitro. J Histochem Cytochem (2010) 1.24
Signaling mechanisms that regulate actin-based motility processes in the nervous system. J Neurochem (2002) 1.22
Kindlin-2 is required for myocyte elongation and is essential for myogenesis. BMC Cell Biol (2008) 1.22
Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol (2006) 1.19
Insulin resistance in the nervous system. Trends Endocrinol Metab (2012) 1.18
DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep (2010) 1.18
Accelerated neuritogenesis and maturation of primary spinal motor neurons in response to nanofibers. Dev Neurobiol (2010) 1.17
Stem cell technology for the study and treatment of motor neuron diseases. Regen Med (2011) 1.16
Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy. Acta Neuropathol (2010) 1.16
Update on diabetic neuropathy. Curr Opin Neurol (2002) 1.16
The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst (2004) 1.15
Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets (2008) 1.14
The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain (2011) 1.12
Membrane traffic and muscle: lessons from human disease. Traffic (2008) 1.12
Neuroinflammation, COX-2, and ALS--a dual role? Exp Neurol (2004) 1.10
Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunol (2011) 1.08
New insights into the mechanisms of diabetic neuropathy. Rev Endocr Metab Disord (2004) 1.08
Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice. Diabetes (2008) 1.07
Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res (2006) 1.07
Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine (Phila Pa 1976) (2011) 1.07
Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. J Neuropathol Exp Neurol (2009) 1.06
Substrate patterning: an emerging technology for the study of neuronal behavior. Exp Neurol (2003) 1.06
Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice. Endocrinology (2008) 1.06
Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis (2008) 1.06
Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care (2010) 1.05
Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation. Muscle Nerve (2009) 1.05
Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid Redox Signal (2009) 1.04
Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. Diabetes (2011) 1.04
Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery (2014) 1.04
The effects of anesthesia on measures of nerve conduction velocity in male C57Bl6/J mice. Neurosci Lett (2010) 1.03
N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene (2003) 1.03
Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury. Antioxid Redox Signal (2005) 1.02
Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev Neurobiol (2009) 1.02
Skeletal muscle weakness due to deficiency of CuZn-superoxide dismutase is associated with loss of functional innervation. Am J Physiol Regul Integr Comp Physiol (2011) 1.01
Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. Endocrinology (2011) 1.01
Insulin-like growth factors in the peripheral nervous system. Endocrinology (2008) 1.00
Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene (2004) 0.99
p38 mediates mechanical allodynia in a mouse model of type 2 diabetes. Mol Pain (2010) 0.99
Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS One (2012) 0.99
Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors (2009) 0.98
The evaluation of distal symmetric polyneuropathy: a physician survey of clinical practice. Arch Neurol (2011) 0.97
Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes. Antioxid Redox Signal (2011) 0.97
Optimization of immunosuppressive therapy for spinal grafting of human spinal stem cells in a rat model of ALS. Cell Transplant (2011) 0.97
Altered excitation-inhibition balance in the brain of patients with diabetic neuropathy. Acad Radiol (2012) 0.97
Nitrotyrosine as a marker for peroxynitrite-induced neurotoxicity: the beginning or the end of the end of dopamine neurons? J Neurochem (2004) 0.96
Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem (2002) 0.96
Integrin expression regulates neuroblastoma attachment and migration. Neoplasia (2004) 0.96
Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes. J Endocrinol (2013) 0.95
Insulin-like growth factors in the treatment of neurological disease. Endocr Dev (2005) 0.95
Diabetic neuropathy: one disease or two? Curr Opin Neurol (2012) 0.95
The antioxidant response as a drug target in diabetic neuropathy. Curr Drug Targets (2008) 0.94
Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.94